Cidara Therapeutics

San Diego, United States Founded: 2013 • Age: 13 yrs Acquired By Merck
Novel anti-infectives for bacterial and fungal infections are developed.

About Cidara Therapeutics

Cidara Therapeutics is a company based in San Diego (United States) founded in 2013 was acquired by Merck in November 2025.. Cidara Therapeutics has raised $78.35 million across 8 funding rounds from investors including Merck, Fidelity Investments and NIH. The company has 38 employees as of December 31, 2024. Cidara Therapeutics offers products and services including Cloudbreak Platform. Cidara Therapeutics operates in a competitive market with competitors including BeiGene, Biological E, Vir Biotechnology, BioNTech and Freeline, among others.

  • Headquarter San Diego, United States
  • Employees 38 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cidara Therapeutics, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $1.27 M
    -94.52
    as on Dec 31, 2024
  • Net Profit
    $-168.03 M
    -632.75
    as on Dec 31, 2024
  • EBITDA
    $-90.99 M
    -237.71
    as on Dec 31, 2024
  • Total Equity Funding
    $78.35 M (USD)

    in 8 rounds

  • Latest Funding Round
    $105 M (USD), Post-IPO

    Nov 21, 2024

  • Investors
    Merck

    & 23 more

  • Employee Count
    38

    as on Dec 31, 2024

  • Acquired by
    Merck

    (Nov 14, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Cidara Therapeutics

Cidara Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CDTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: CDTX . Sector: Health technology · USA

Products & Services of Cidara Therapeutics

Cidara Therapeutics offers a comprehensive portfolio of products and services, including Cloudbreak Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform creates drug-Fc conjugates for targeted disease treatment.

People of Cidara Therapeutics
Headcount 50-200
Employee Profiles 25
Board Members and Advisors 9
Employee Profiles
People
Nicole Davarpanah
SVP, Translational Research & Development
People
Allison Lewis
SVP, People & Culture
People
Shane Ward
COO & Chief Legal Officer
People
Jeffrey Stein
President, CEO & Director

Unlock access to complete

Board Members and Advisors
people
Chrysa Mineo
Director

Unlock access to complete

Funding Insights of Cidara Therapeutics

Cidara Therapeutics has successfully raised a total of $78.35M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $105 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 8
  • Last Round Post-IPO — $105.0M
  • First Round

    (16 Jun 2014)

  • Investors Count 23
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2024 Amount Post-IPO - Cidara Therapeutics Valuation

investors

Apr, 2024 Amount Post-IPO - Cidara Therapeutics Valuation

investors

Sep, 2019 Amount Post-IPO - Cidara Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cidara Therapeutics

Cidara Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Fidelity Investments and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on tech sectors
Founded Year Domain Location
-
Founded Year Domain Location
US private equity investments are managed by BVF Partners.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cidara Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cidara Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cidara Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cidara Therapeutics

Cidara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biological E, Vir Biotechnology, BioNTech and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Vaccines and therapeutics for multiple diseases are developed and marketed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Immunotherapeutics for cancer and other diseases are developed.
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cidara Therapeutics

Frequently Asked Questions about Cidara Therapeutics

When was Cidara Therapeutics founded?

Cidara Therapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Cidara Therapeutics located?

Cidara Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Who is the current CEO of Cidara Therapeutics?

Jeffrey Stein is the current CEO of Cidara Therapeutics.

Is Cidara Therapeutics a funded company?

Cidara Therapeutics is a funded company, having raised a total of $78.35M across 8 funding rounds to date. The company's 1st funding round was a Post-IPO of $9.01M, raised on Jun 16, 2014.

How many employees does Cidara Therapeutics have?

As of Dec 31, 2024, the latest employee count at Cidara Therapeutics is 38.

What is the annual revenue of Cidara Therapeutics?

Annual revenue of Cidara Therapeutics is $1.27M as on Dec 31, 2024.

What does Cidara Therapeutics do?

Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.

Who are the top competitors of Cidara Therapeutics?

Cidara Therapeutics's top competitors include BeiGene, Vaxcyte and BioNTech.

What products or services does Cidara Therapeutics offer?

Cidara Therapeutics offers Cloudbreak Platform.

Is Cidara Therapeutics publicly traded?

Yes, Cidara Therapeutics is publicly traded on NASDAQ under the ticker symbol CDTX.

Who are Cidara Therapeutics's investors?

Cidara Therapeutics has 24 investors. Key investors include Merck, Fidelity Investments, NIH, RA Capital, and Frazier Healthcare Partners.

What is Cidara Therapeutics's ticker symbol?

The ticker symbol of Cidara Therapeutics is CDTX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available